Neurovascular

WILLOWBROOK, Ill. — September 14, 2026 Pharmazz, Inc. announced that the U.S. Food and Drug Administration (FDA) Office of...

ALAMEDA, California, July 22, 2026 Penumbra, Inc. has announced positive results from the THUNDER Investigational Device Exemption (IDE) study,...

Maple Grove, Minn., July 22, 2026 Serenity Medical announced new four- to five-year clinical data demonstrating the long-term effectiveness...

SEATTLE & YOKNEAM, Israel, July 21, 2026 Rapid Medical announced U.S. Food and Drug Administration (FDA) clearance of DRIVEWIRE™...

BEVERLY, Mass., July 7, 2026 Akston Biosciences Corporation has announced encouraging preclinical data demonstrating that its investigational NGF-targeting Ambifect®...

ALAMEDA, Calif., July 7, 2026 Penumbra, Inc., a global leader in thrombectomy technologies, has announced the first patient enrollment...